Peri-Operative Safety: Preventing EuDKA in SGLT-2 Patients

Created using ChatSlide

This presentation explores the clinical use and safety implications of SGLT-2 inhibitors, focusing on their mechanism to increase urinary glucose excretion and their application in diabetes and cardiovascular care. It addresses the rare but serious risk of euglycaemic diabetic ketoacidosis, emphasising MHRA guidance. A safety care bundle to mitigate perioperative risks is detailed, including guidelines for withholding and restarting therapy. A structured 12-week intervention plan highlights...